M
Mary J. Fidler
Researcher at Rush University Medical Center
Publications - 116
Citations - 7395
Mary J. Fidler is an academic researcher from Rush University Medical Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 21, co-authored 95 publications receiving 5610 citations. Previous affiliations of Mary J. Fidler include Trinity School of Medicine.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen,Denis Soulières,Christophe Le Tourneau,Christophe Le Tourneau,Christophe Le Tourneau,José Dinis,Lisa Licitra,Myung-Ju Ahn,Ainara Soria,Jean-Pascal Machiels,Jean-Pascal Machiels,Nicolas Mach,Ranee Mehra,Barbara Burtness,Pingye Zhang,Jonathan D. Cheng,Ramona F. Swaby,Kevin J. Harrington,Kevin J. Harrington,Mirelis Acosta-Rivera,Douglas Adkins,Morteza Aghmesheh,Mario Airoldi,Eduardas Aleknavicius,Yousuf Al-Farhat,Alain Algazi,Salah Almokadem,Anna Alyasova,Jessica Bauman,Marco Benasso,Alfonso Berrocal,Victoria Bray,Barbara Ann Burtness,F. Caponigro,Ana Castro,Terrence P. Cescon,Kelvin K. W. Chan,Arvind Chaudhry,Bruno Chauffert,Ezra W. Cohen,Tibor Csoszi,J. de Boer,Jean-Pierre Delord,Andreas Dietz,Charlotte Dupuis,Laurence Digue,Jozsef Erfan,Yolanda Alvarez,Mererid Evans,Mary J. Fidler,Martin David Forster,Signe Friesland,Apar Kishor Ganti,Lionnel Geoffrois,Cliona Grant,Viktor Gruenwald,Kevin J. Harrington,Thomas K. Hoffmann,Geza Horvai,Arturas Inciura,Raymond Woo-Jun Jang,Petra Jankowska,Antonio Jimeno,Mano Joseph,Alejandro Juarez Ramiro,Boguslawa Karaszewska,Andrzej Kawecki,Ulrich Keilholz,Ulrich Keller,Sung Bae Kim,Judit Kocsis,Nuria Kotecki,Mark F. Kozloff,Julio Lambea,Laszlo Landherr,Yuri Lantsukhay,Sergey Alexandrovich Lazarev,Lip Way Lee,Igor Dmitrievich Lifirenko,Danko Martincic,Oleg Vladmirovhich Matorin,Margaret McGrath,Krzysztof Misiukiewicz,John C. Morris,Fagim Fanisovich Mufazalov,Jiaxin Niu,Devraj Pamoorthy Srinivasan,Pedro Perez Segura,Daniel Rauch,Maria Leonor Ribeiro,Cristina P. Rodriguez,Frederic Rolland,Antonio Russo,Agnes Ruzsa,Frederico Sanches,Sang-Won Shin,Mikhail Shtiveland,Pol Specenier,Eva Szekanecz,Judit Szota,Carla M.L. van Herpen,Hector A. Velez-Cortes,William V. Walsh,Stefan Wilop,Ralph Winterhalder,Marek Z. Wojtukiewicz,Deborah Wong,Dan P. Zandberg +107 more
TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.
Journal ArticleDOI
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel,Nathan A. Pennell,Mary J. Fidler,Balazs Halmos,Philip Bonomi,James P. Stevenson,Bryan J. Schneider,Ammar Sukari,Jaclyn Ventimiglia,Wei Chen,Cathy Galasso,Antoinette J. Wozniak,Julie L. Boerner,Gregory P. Kalemkerian +13 more
TL;DR: Installing maintenance pembrolizumab in patients with extensive‐stage SCLC after treatment with platinum and etoposide did not appear to improve median PFS compared with the historical data, however, the 1‐year PFS rate of 13% and OS rate of 37% suggest that a subset of patients did benefit from pembrolexumab.
Journal ArticleDOI
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
Jenna H. Newman,C. Brent Chesson,Nora L. Herzog,Praveen K. Bommareddy,Salvatore M. Aspromonte,Russell J. Pepe,Ricardo Estupinian,Ricardo Estupinian,Mones M. Aboelatta,Mones M. Aboelatta,Stuti Buddhadev,Saeed Tarabichi,Michael J. Lee,Shengguo Li,Daniel J. Medina,Eileena F. Giurini,Kajal Gupta,Gabriel Guevara-Aleman,Marco Rossi,Christina Nowicki,Abdulkareem Abed,Josef W. Goldufsky,Joseph R. Broucek,Joseph R. Broucek,Raquel E. Redondo,Raquel E. Redondo,David Rotter,Sachin R. Jhawar,Sachin R. Jhawar,Shang Jui Wang,Frederick J. Kohlhapp,Howard L. Kaufman,Paul G. Thomas,Paul G. Thomas,Vineet Gupta,Timothy M. Kuzel,Jochen Reiser,Joyce Paras,Michael P. Kane,Eric A. Singer,Jyoti Malhotra,Lisa K. Denzin,Derek B. Sant'Angelo,Arnold B. Rabson,Leonard Y. Lee,Ahmed Lasfar,John Langenfeld,Jason M. Schenkel,Jason M. Schenkel,Mary J. Fidler,Emily S. Ruiz,Emily S. Ruiz,Amanda L. Marzo,Jai S. Rudra,Ann W. Silk,Andrew Zloza,Andrew Zloza +56 more
TL;DR: It is reported that unadjuvanted seasonal influenza vaccination via intratumoral, but not intramuscular, injection converts “cold” tumors to hot, generates systemic CD8+ T cell-mediated antitumor immunity, and sensitizes resistant tumors to checkpoint blockade, and proposes that antipathogen vaccines may be utilized for both infection prevention and repurposing as a cancer immunotherapy.
Journal ArticleDOI
Esophageal carcinoma advances in treatment results for locally advanced disease: review
TL;DR: Chemo (PF) before surgery improved overall survival (OS) in those patients in most of the randomized trials and in meta-analyses and it was found that those patients with pathologic complete response to the initial treatment did better than those who had no improvement at all.